The study from Yeh et al., also discovered that the levels of C-C chemokine receptor type 2 (CCR2) and CD180 were found to be significantly downregulated in whole blood samples exposed to AZD5153 from patients with multiple types of cancer (Fig. 2).111 Originally identified as BETi targets using transcriptomic analysis, the downregulation of these immune components might link BETi activity with the modulation of immune infiltrates. This evidence concerns the gene CCR2 and cancer.